Meralgia Paresthetica Clinical Trial
Official title:
Does Obesity EffectThe Successful Response to the Pulsed Radiofrequency of Lateral Femoral Cutaneous Nerve in Meralgia Parestetica? : A Retrospective Cohort Study
Verified date | April 2024 |
Source | Mersin Training and Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
In the current retrospective cohort study, conducted by both pain specialists and neurophysiologists, the primary outcome was to search for the effect of obesity on the efficacy of PRF of LFCN in refractory MP for 6 months. Secondary outcomes were to identify the clinical and diagnostic features of the MP.
Status | Completed |
Enrollment | 30 |
Est. completion date | December 6, 2023 |
Est. primary completion date | November 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - older than 18 years treated with PRF neuromodulation of LFCN for MP - followed up at least 6 months in the pain clinic of the tertiary hospital between January 2020 and August 2023. Exclusion Criteria: - inadequate follow-up or missing documentation - If a new analgesic drug was prescribed during the follow-up period that could affect the evaluation of outcomes, the patients were also excluded. - Patients who missed appointments, or were unable to communicate with; were not included in the study. - Patients with secondary entrapment neuropathy (e.g., diabetes, inflammatory arthritis, hypothyroidism), malignancy, pregnancy, skin infection in the inguinal region or dermatitis, lumbar radiculopathy, polyneuropathy, and cardiac pacemakers were excluded. - In the SSEP analysis, when the latency of LFCN was not evaluated in both sides, these patients were not also included in the study. |
Country | Name | City | State |
---|---|---|---|
Turkey | Suna Askin Turan | Mersin |
Lead Sponsor | Collaborator |
---|---|
Mersin Training and Research Hospital |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | response to PRF | loss of neuropathic pain, lasting at least 6 months was defined as a positive categorical outcome. Neuropathic pain was assessed with Douleur Neuropathique 4 questionnaire (DN4) at baseline, and at 1., 3, 6 months by the pain specialist authors. DN4 consisted of 10 items. The first seven items were associated with the patients' subjective compliants related to pain and sensational variations while the last three items were associated with the clinical findings. Those patients who had a score = 4were considered to have neuropathic pain. Patients with a positive outcome at the 1 or 3 month follow-up,but did not come again were excluded from the study. After the data collection, the patients wer divided into two groups: responders with a positive outcome and nonresponders with a negative outcome.MP for 6 months. Age, sex, body mass index (BMI), employment, tight clothing, belts, carrying things at the back of pants were asked in detail at the initial visit of the Pain Clinic. | 6 months | |
Secondary | Secondary outcomes were to identify the clinical and diagnostic features of the MP | Secondary outcomes were to identify the clinical and diagnostic features of the MP. The outcome was assesed by the clinical and electrophysiological data collected from the hospital records. The data was analyzed deeply. | 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04747119 -
Effect of MET on Meralgia Paraesthesia Postpartum "Muscle Energy Technique"
|
N/A | |
Completed |
NCT02577510 -
Comparing Ways to Freeze the Nerve That Provides Thigh Sensation
|
Phase 3 | |
Withdrawn |
NCT04046406 -
Pelvic Pain Treated With MR-guided Cryoanalgesia
|
N/A | |
Recruiting |
NCT05893732 -
HILT for Meralgia Paresthetica: A Randomized Controlled Trial
|
N/A | |
Completed |
NCT06251882 -
Efficacy of Ultrasound-guided Injection of 5% Dextrose for Meralgia Paresthesia
|
N/A | |
Completed |
NCT04004052 -
Conservative Treatment and Ultrasound Guided Injection for Treatment Meralgia Paresthetica
|
N/A | |
Completed |
NCT04499911 -
Efficacy of Neural Prolotherapy in Treatment of Meralgia Paresthetica
|
N/A |